Chandan Healthcare Limited Divests Entire Stake in Pharmacy to Focus on High-Margin Diagnostics
Chandan Healthcare Limited (CHL) has approved a strategic divestment of its entire stake in Chandan Pharmacy Limited (CPL). The transaction, completed following a Board meeting on August 6, 2026, involves selling the company’s 53.56% shareholding in CPL to Chandan Hospital Limited, a group entity.The sale was executed for a consideration of Rs 31,31,36,168, which represents the proportionate value based on an independent valuation report dated August 3, 2026, prepared by Mr. Gaurang Gaurav, Registered Valuer. Upon closure of the deal, CHL’s holding in CPL will reduce to Nil, and CPL will cease being a subsidiary of Chandan Healthcare Limited.
The decision reflects a comprehensive review of CHL's business mix and long-term capital allocation priorities, aiming to sharpen its focus on the higher-margin diagnostics sector.
Strategic Rationale for Divestment
The Board determined that the divestiture is necessary to deliver value and improve the company’s operational structure. The decision is underpinned by three key factors: concentrating on core growth areas, enhancing financial transparency, and exiting a revenue mix that was heavily weighted towards low-margin business.The primary rationale points include:
- Focusing on Diagnostics: Divestment allows management bandwidth and capital to be concentrated on the diagnostics business, which consistently offers longer runway for profitable growth and materially higher EBITDA margins compared to the pharmacy segment.
- Enhanced Investor Readability: By deconsolidating the pharmacy operations, the standalone financials of Chandan Healthcare Limited will accurately reflect the scale, faster growth trajectory, and profitability of its core diagnostics operations.
- Margin Improvement: Over 70% of CPL's revenue is generated from low-margin B2B supply to Chandan Hospital Limited. The exit from this mix is expected to be margin accretive at the consolidated level going forward.
Key Transaction Details
The following table summarizes the principal terms and conditions of the divestment:| Detail | Description |
|---|---|
| Buyer | Chandan Hospital Limited (A group company) |
| Shares Divested | 1,72,992 equity shares of Rs. 10/- each (53.56% of CPL's paid-up capital) |
| Consideration | Rs 31,31,36,168 |
| Valuation Basis | Independent valuation report dated August 3, 2026 by Mr. Gaurang Gaurav, Registered Valuer |
| Resulting Holding | Nil (0%) CPL ceases to be a subsidiary of CHL |
| Use of Proceeds | Development of new diagnostic centres for the company's higher-EBITDA core business |
| Board Approval Date | August 6, 2026 |
Benefits and Outlook
The transaction is expected to significantly benefit shareholders by improving the overall margin profile. With the lower-margin pharmacy operations removed from consolidation, CHL’s reported EBITDA margins are anticipated to reflect the stronger economics of its diagnostics business more clearly.Proceeds generated from the sale have been designated to bolster the company's balance sheet and provide capital for expanding the high-return diagnostics network, including new center rollouts and capacity additions. This redeployment of funds into higher-EBITDA assets is expected to be accretive to consolidated profitability in the future.
Post-completion, Chandan Healthcare Limited will operate as a focused diagnostics entity within the broader Chandan Group. The Board remains committed to disciplined capital allocation and building long-term value for shareholders through its core diagnostics business.
CHANDAN Stock Price Movement
Chandan Healthcare Limited shares today slipped by 3.86%, closing the post-market session at ₹231.45 following a sharp drop of ₹9.30. The stock's intraday trading movement was contained within a range that stretched from a low of ₹225 to a high of ₹240.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: